Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7428731 in EGFRvIII-positive Glioblastoma
NCT05187624Phase 1Completed
- Sponsor
- Roche
- Start
- Apr 2022
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of RO7428731 in glioblastoma (GBM) (4 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Adverse Events up to 15 months and Percentage of Participants with Dose Limiting Toxicities. Started Apr 2022; status: completed.
02
Drugs
RO7428731
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05187624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187624.